Overview

Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)

Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
In this pilot trial, 150 confirmed COVID-19 individuals will be randomly assigned to 1 of 5 groups: distilled water, CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA), Oral-B Mouth Sore (Oral-B, USA), Crest Pro-Health Multi-Protection (Crest, USA), or Listerine Zero (Johnson and Johnson, USA). Study participants will be asked to rinse/gargle with 10-20ml (according to the rinse instructions) of the assigned solutions 4 times per day, for 30-60 seconds, for 4 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
Rowpar Pharmaceuticals, Inc.
Treatments:
Cetylpyridinium
Chlorine dioxide
Hydrogen Peroxide
Listerine